Latest Insider Transactions at Regenxbio Inc. (RGNX)
This section provides a real-time view of insider transactions for Regenxbio Inc. (RGNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENXBIO Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENXBIO Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2024
|
Steve Pakola Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,878
+9.69%
|
$283,316
$22.25 P/Share
|
|
Feb 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-1.79%
|
$240,000
$16.67 P/Share
|
|
Feb 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Jan 16
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
45,000
-9.93%
|
$675,000
$15.18 P/Share
|
|
Jan 16
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+9.04%
|
$135,000
$3.76 P/Share
|
|
Jan 03
2024
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,237
-13.85%
|
$293,029
$17.39 P/Share
|
|
Jan 02
2024
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,462
+23.77%
|
-
|
|
Jan 02
2024
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,120
-8.73%
|
$138,040
$17.95 P/Share
|
|
Jan 02
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,462
+23.55%
|
-
|
|
Jan 02
2024
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,410
-8.87%
|
$142,970
$17.95 P/Share
|
|
Jan 02
2024
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,051
+20.48%
|
-
|
|
Jan 02
2024
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,385
-10.11%
|
$176,545
$17.95 P/Share
|
|
Jan 02
2024
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,026
+6.61%
|
-
|
|
Jan 02
2024
|
Vittal Vasista Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-2.11%
|
$77,078
$17.95 P/Share
|
|
Jan 02
2024
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,615
+23.02%
|
-
|
|
Jan 02
2024
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,893
-8.86%
|
$134,181
$17.95 P/Share
|
|
Jan 02
2024
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
64,103
+13.58%
|
-
|
|
Jan 02
2024
|
Kenneth T. Mills |
SELL
Payment of exercise price or tax liability
|
Direct |
11,357
-3.2%
|
$193,069
$17.95 P/Share
|
|
Dec 19
2023
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
45,000
-11.24%
|
$855,000
$19.68 P/Share
|
|
Dec 19
2023
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+5.1%
|
$90,000
$2.31 P/Share
|
|
Jun 30
2023
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,123
+1.17%
|
$17,968
$16.99 P/Share
|
|
Jun 02
2023
|
Jennifer Zachary |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+26.83%
|
-
|
|
Jun 02
2023
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
Jun 02
2023
|
Argeris N Karabelas |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
Jun 02
2023
|
Alexandra Glucksmann |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
Jun 02
2023
|
George V Migausky |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
Jun 02
2023
|
David C Stump |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
Jun 02
2023
|
Daniel Tasse |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
Jun 02
2023
|
Allan M. Fox |
BUY
Grant, award, or other acquisition
|
Direct |
3,486
+34.92%
|
-
|
|
May 31
2023
|
Vittal Vasista Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+14.0%
|
$0
$0.85 P/Share
|
|
Jan 03
2023
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,940
+43.28%
|
-
|
|
Jan 03
2023
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,843
-8.03%
|
$40,546
$22.68 P/Share
|
|
Jan 03
2023
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
54,753
+13.35%
|
-
|
|
Jan 03
2023
|
Kenneth T. Mills |
SELL
Payment of exercise price or tax liability
|
Direct |
9,308
-3.0%
|
$204,776
$22.68 P/Share
|
|
Jan 03
2023
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,930
+41.5%
|
-
|
|
Jan 03
2023
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,058
-7.08%
|
$45,276
$22.68 P/Share
|
|
Jan 03
2023
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,588
+46.85%
|
-
|
|
Jan 03
2023
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,138
-20.49%
|
$69,036
$22.17 P/Share
|
|
Jan 03
2023
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,837
-10.71%
|
$40,414
$22.68 P/Share
|
|
Jan 03
2023
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,945
+42.22%
|
-
|
|
Jan 03
2023
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,076
-7.66%
|
$45,672
$22.68 P/Share
|
|
Jan 03
2023
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,174
+20.42%
|
-
|
|
Jan 03
2023
|
Vittal Vasista Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,333
-0.99%
|
$29,326
$22.68 P/Share
|
|
Aug 30
2022
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,400
-1.74%
|
$72,000
$30.24 P/Share
|
|
Aug 05
2022
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,280
-11.16%
|
$604,800
$35.19 P/Share
|
|
Aug 04
2022
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400
-0.26%
|
$14,000
$35.0 P/Share
|
|
Aug 01
2022
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,400
-1.52%
|
$74,400
$31.25 P/Share
|
|
Jul 14
2022
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
468
-0.3%
|
$14,040
$30.0 P/Share
|
|
Jul 13
2022
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,332
-2.67%
|
$129,960
$30.01 P/Share
|
|
Jun 30
2022
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
728
+0.77%
|
$15,288
$21.0 P/Share
|